Almirall updates its earnings calendar, shares watched ahead of next catalyst

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-26, 13:32.

Almirall (ES0157097017) is preparing for its next earnings season with a published financial calendar and several investor events on the agenda, as shown on its Madrid listing on BME. The Spanish dermatology specialist remains closely tracked by analysts ahead of the next quarterly update, according to compiled estimates on MarketScreener.

What the company’s calendar shows

According to the company’s own financial calendar, Almirall plans to present its next quarterly results and related conference call in the second half of 2026, following the pattern of past half-year and nine-month reports disclosed through the Spanish CNMV and its investor relations site. The group typically pairs its earnings releases with a webcast and Q&A session for investors and analysts, ensuring guidance commentary and an update on key dermatology launches. An overview of the 2026 schedule can be found in the company’s official investor relations calendar.

Recent communications have followed the standard sequence seen in previous years, with full-year results presented in February, followed by a first-half update in late July and nine-month figures around late October, all published via CNMV filings and mirrored on the Almirall investor site. The company also tends to host capital markets presentations or conference appearances around these dates, giving investors additional detail on pipeline progress and commercial execution in Europe and the United States. This recurring pattern provides a framework for market participants on BME as they position around upcoming disclosure dates.

Analyst expectations and peer comparison

Consensus data compiled by MarketScreener indicates that a majority of covering analysts currently rate Almirall between Hold and Buy, with an average 12-month price target above the recent Madrid trading range, underlining a cautiously constructive stance on the stock. The same consensus set reflects expectations for mid-single-digit revenue growth and margin improvement over the next two financial years, supported by dermatology launches and portfolio optimization. These figures are based on aggregated broker models, as summarized in the MarketScreener consensus page for Almirall.

In sector terms, Almirall is often compared with European mid-cap specialty pharma peers such as Grifols and UCB, which also focus on biologics and complex therapies, although those groups operate in hematology and neurology in addition to immunology. While larger multinational players like Novartis and Sanofi dominate the broader pharmaceuticals space, Almirall’s focus on dermatology and inflammation positions it in a niche where product differentiation and lifecycle management are key drivers of earnings. Investors on the Madrid exchange monitor not only the company’s own guidance but also regulatory and pricing developments that affect dermatology portfolios across Europe, as highlighted in recent European pharma sector notes from banks such as UBS and Deutsche Bank, summarized by financial media including Reuters sector coverage.

The dermatology products behind the stock

Almirall generates most of its revenue from prescription dermatology medicines targeting chronic inflammatory skin diseases such as psoriasis and atopic dermatitis, complemented by aesthetics products. Key brands include Ilumetri, a biologic indicated for moderate-to-severe plaque psoriasis, and Skilarence, an oral systemic therapy for psoriasis in adult patients. The company also markets a portfolio of topical treatments and is investing in pipeline assets aimed at immuno-dermatology and other dermatologic conditions, according to its latest product overview on the investor site.

Where the shares trade today

The Almirall shares (ES0157097017) most recently traded on the Madrid Stock Exchange at around 9 euros on 2026-06-26, 11:30, according to BME price data, with the company’s market capitalization standing in the low single-digit billion euro range.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell any financial instrument. All data are based on sources believed to be reliable, but no guarantee is given for their accuracy or completeness. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.